Green 2002a.

Methods	DESIGN ‐cross‐over trial ‐4 weeks for each of the 4 periods ‐1‐month wash‐out between periods ALLOCATION ‐Random ‐Means of randomisation: not specified ‐Mode of allocation: not specified BLINDING ‐double‐blind ‐mode of blinding: not specified WITHDRAWL/DROPOUTS ‐not described JADAD's Quality score = 2 Confirmation of methodology ‐ not obtained
Participants	SYMPTOMATIC PARTICIPANTS RANDOMISED N = 49 for each of 4 periods WITHDRAWALS not reported AGE: not reported GENDER (% male) not reported SEVERITY: ?mild‐moderate asthma BASELINE % predicted FEV1 ± (SD) not reported BUD 800: BUD 200 + Montelukast: BUD 200 + Formoterol: BUD 200 + Placebo: ALLERGIC RHINITIS: ‐not reported ASTHMA DURATION: ‐not reported ELIGIBILITY CRITERIA ‐not reported EXCLUSION CRITERIA ‐not reported
Interventions	PROTOCOL: AL + ICS vs HIGHER dose ICS DURATION: ‐Run‐in Period: not described ‐Intervention Period: 4 weeks ‐Wash‐out period: 4 weeks TEST GROUP 1 BUD 100 mcg bid + Montelukast 10 mg die TEST GROUP 2 (not used in this review) BUD 100 mcg bid + formoterol CONTROL GROUP 1 4 x ICS: BUD 400 mcg bid CONTROL GROUP 2 (not used in this review) BUD 100 mcg bid DEVICE ‐not specified CO‐TREATMENT: ‐not reported
Outcomes	INTENTION‐TO‐TREAT ANALYSES PULMONARY FUNCTION TESTS ‐change in FEV1 (L) ‐*change in AM PEF (L/min) SYMPTOM SCORES (PP) ‐change in symptom score (scale 0 to 6) FUNCTIONAL STATUS (PP) ‐change in mean daily use of B2‐agonist (puffs/day) ‐change in quality of life score (range 1‐7) ‐change in nocturnal awakenings INFLAMATORY MARKERS ‐change in peripheral blood eosinophil count ADVERSE EFFECTS ‐not reported WITHDRAWALS ‐not reported * primary outcome
Notes	‐Abstract 2002 ‐Funding: not specified ‐Confirmation of methodology and data extraction: not obtained. User‐defined order: 20 (mean intervention BUD dose in mcg/day X 0.1)
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	Information not available (Cochrane Grade B)